Subscribe to RSS
DOI: 10.1016/j.homp.2011.01.002
New homeopathic medicines: use of modern drugs according to the principle of similitude
Subject Editor:
Publication History
Received05 August 2010
revised08 November 2010
accepted31 January 2011
Publication Date:
27 December 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00034926/201104/lookinside/thumbnails/10-1016-j-homp-2011-01-002-1.jpg)
Background: The homeopathic method is based on the application of the principle of therapeutic similitude (similia similibus curentur), using medicines that cause effects similar to the symptoms of disease in order to stimulate the reaction of the organism against disturbances. Such vital, homeostatic or paradoxical reaction of the organism can be scientifically explained on the basis of the rebound effect of modern drugs.
Aims: This article presents the conclusion of a study aiming at a method to use modern drugs with homeopathic criteria.
Methods: Adverse effects as catalogued in United States Pharmacopoeia Dispensing Information Drug monographs were collected.
Results: A homeopathic materia medica and repertory comprising 1251 modern drugs to be employed according to the principle of therapeutic similitude was developed.
Conclusion: Besides supplying a basis for homeopathy as a medical rationale related to scientific pharmacology, this study makes available a method that may broaden the scope of intervention of homeopathy in present day diseases.
-
References
- 1 Hahnemann S. Organon of medicine. [Boericke W, Trans.] 6th edn. New Delhi: B. Jain Publishers; 1991.
- 2 Hahnemann S. Essay on a new principle for ascertaining the curative power of drugs, with a few glances at those hitherto employed. In: Dudgeon R.E. The Lesser Writings of Samuel Hahnemann. 1995. New Delhi: B. Jain Publishers; [Reprint edition].
- 3 Teixeira M.Z. Semelhante cura semelhante: o princípio de cura homeopático fundamentado pela racionalidade médica e científica. Similar cures similar: the homeopathic cure principle based by the medical and scientific rationality. São Paulo: Editorial Petrus; 1998.
- 4 Teixeira M.Z. Similitude in modern pharmacology. Homeopathy 1999; 88 (03) 112-120.
- 5 Teixeira M.Z. Evidence of the principle of similitude in modern fatal iatrogenic events. Homeopathy 2006; 95 (04) 229-236.
- 6 Teixeira M.Z. NSAIDs, myocardial infarction, rebound effect and similitude. Homeopathy 2007; 96 (01) 67-68.
- 7 Teixeira M.Z. Bronchodilators, fatal asthma, rebound effect and similitude. Homeopathy 2007; 96 (02) 135-137.
- 8 Teixeira M.Z. Antidepressants, suicidality and rebound effect: evidence of similitude?. Homeopathy 2009; 98 (01) 114-121.
- 9 Teixeira M.Z. Statins withdrawal, vascular complications, rebound effect and similitude. Homeopathy 2010; 99 (04) 255-262.
- 10 Teixeira M.Z. Homeopathic use of modern medicines: utilisation of the curative rebound effect. Med Hypotheses 2003; 60 (02) 276-283.
- 11 Teixeira M.Z. ‘Paradoxical strategy for treating chronic diseases’: a therapeutic model used in homeopathy for more than two centuries. Homeopathy 2005; 94 (04) 265-266.
- 12 Dudgeon R.E. Lectures on the theory and practice of homoeopathy. New Delhi: B. Jain Publishers; 1982. [Reprint edition]. Lectures VII e XII.
- 13 Hughes R. A manual of pharmacodynamics. 6th edn. New Delhi: B. Jain Publishers; 1980. [Second reprint edition]. Lecture II.
- 14 Hahnemann S. Some kinds of continued and remittent fevers. In: Dudgeon R.E. The Lesser Writings of Samuel Hahnemann. 1995. New Delhi: B. Jain Publishers; [Reprint edition].
- 15 Hahnemann S. Cure and prevention of scarlet-fever. In: Dudgeon R.E. The Lesser Writings of Samuel Hahnemann. 1995. New Delhi: B. Jain Publishers; [Reprint edition].
- 16 Hahnemann S. On the power of small doses of medicine in general, and of Belladonna in particular. In: Dudgeon R.E. The Lesser Writings of Samuel Hahnemann. 1995. New Delhi: B. Jain Publishers; [Reprint edition].
- 17 Hahnemann S. Treatment of the typhus or hospital fever at present prevailing. In: Dudgeon R.E. The Lesser Writings of Samuel Hahnemann. 1995. New Delhi: B. Jain Publishers; [Reprint edition].
- 18 Hahnemann S. How can small doses of such very attenuated medicines as homoeopathy employs have any action on the sick?. In: Dudgeon R.E. The Lesser Writings of Samuel Hahnemann. 1995. New Delhi: B. Jain Publishers; [Reprint edition].
- 19 Hahnemann S. The medicine of experience. In: Dudgeon R.E. The Lesser Writings of Samuel Hahnemann. 1995. New Delhi: B. Jain Publishers; [Reprint edition].
- 20 Wettemann M. Hahnemann’s use of ‘Fragmenta de viribus medicamentorum’ in his early medical practice: analysis based on a patient file. Med Ges Ghesch 2001; 20: 221-230.
- 21 Hahnemann S. Reine Arzneimittellehre. [German Edition] Ann Arbor: Scholarly Publishing Office, University of Michigan Library; 1830. p. 472.
- 22 Hahnemann S. Materia Medica Pura. New Delhi: B. Jain Publishers; 1994. [Reprint edition]. 2v.
- 23 Hahnemann S. Chronic diseases. [Dudgeon RE, Trans.] New Delhi: B. Jain Publishers; 1983. 2v.
- 24 World Health Organization (WHO), The Uppsala Monitoring Centre. The importance of pharmacovigilance. Safety monitoring of medicinal products. Available from: 2002. http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf.
- 25 European Medicines Agency. Guideline for good clinical practice. Available from: 2002. http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf London.
- 26 World Health Organization (WHO), Council for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. Available from: 2002. http://www.cioms.ch/publications/guidelines/guidelines_nov_2002_blurb.htm Geneva.
- 27 World Health Organization (WHO). Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. Technical report series, No. 850, annex 3. Available from: WHO; 1995. http://apps.who.int/medicinedocs/pdf/whozip13e/whozip13e.pdf.
- 28 United States. Code of Federal Regulations. 21 CFR. Food and drugs. 312 Investigational new drug application. Available from: 2003. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=312 Washington.
- 29 Marodin G., Goldim J.R. Confusions and ambiguities in the classification of adverse events in the clinical research. Rev Esc Enferm USP 2009; 43 (03) 690-696 Available from: http://www.scielo.br/pdf/reeusp/v43n3/en_a27v43n3.pdf.
- 30 The United States Pharmacopeial Convention. The United States pharmacopeia dispensing information. Easton: Mack Printing Co.; 2004.
- 31 World Health Organization (WHO), Council for International Organizations of Medical Sciences. Guidelines for preparing core clinical safety information on drug from CIOMS working group III. Available from: 1995. https://apps.who.int/dsa/cat98/zcioms8.htm Geneva.
- 32 World Health Organization (WHO), The Uppsala Monitoring Centre. Safety monitoring of medicinal products. Guidelines for setting up and running a Pharmacovigilance Centre. Available from: 2000. http://apps.who.int/medicinedocs/en/d/Jh2934e/.
- 33 American Hospital Formulary Service drug information. Bethesda: American Society of Hospital Pharmacists; 2010.
- 34 British Pharmacopoeia Commission. The British pharmacopoeia. Belfast: The Stationery Office; 2010.
- 35 European Pharmacopoeia Commission. European pharmacopoeia. 6th edn. Belfast: The Stationery Office; 2009.
- 36 Sweetman S.C. Martindale: the complete drug reference. 36th edn. London: The Pharmaceutical Press; 2009.
- 37 United States, Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. Form FDA 3500A – mandatory reporting. Available from: 2009. http://www.fda.gov/downloads/Safety/MedWatch/HowToReport/DownloadForms/UCM082728.pdf Washington.
- 38 Teixeira M.Z. New homeopathic medicines: use of modern drugs according to principle of similitude. Available from: São Paulo: Marcus Zulian Teixeira; 2010. www.newhomeopathicmedicines.com 3v.